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Trends in excess mortality associated with atrial fibrillation over 
45 years (Framingham Heart Study): community based cohort 
study
Nicklas Vinter,1,2 Qiuxi Huang,3 Morten Fenger-Grøn,4 Lars Frost,1 Emelia J Benjamin,5,6  
Ludovic Trinquart3,6
ABSTRACT
OBJECTIVE
To assess temporal trends in the association between 
newly diagnosed atrial fibrillation and death.
DESIGN
Community based cohort study.
SETTING
Framingham Heart Study cohort, in 1972-85, 1986-
2000, and 2001-15 (periods 1-3, respectively), in 
Framingham, MA, USA.
PARTICIPANTS
Participants with no atrial fibrillation, aged 45-95 in 
each time period, and identified with newly diagnosed 
atrial fibrillation (or atrial flutter) during each time 
period.
MAIN OUTCOME MEASURES
The main outcome was all cause mortality. Hazard 
ratios for the association between time varying atrial 
fibrillation and all cause mortality were calculated 
with adjustment for time varying confounding factors. 
The difference in restricted mean survival times, 
adjusted for confounders, between participants with 
atrial fibrillation and matched referents at 10 years 
after a diagnosis of atrial fibrillation was estimated. 
Meta-regression was used to test for linear trends in 
hazard ratios and restricted mean survival times over 
the different time periods.
RESULTS
5671 participants were selected in time period 1, 
6177 in period 2, and 6174 in period 3. Adjusted 
hazard ratios for all cause mortality between 
participants with and without atrial fibrillation were 
1.9 (95% confidence interval 1.7 to 2.2) in time period 
1, 1.4 (1.3 to 1.6) in period 2, and 1.7 (1.5 to 2.0) 
in period 3 (Ptrend=0.70). Ten years after diagnosis of 
atrial fibrillation, the adjusted difference in restricted 
mean survival times between participants with atrial 
fibrillation and matched referents decreased by 
31%, from −2.9 years (95% confidence interval −3.2 
to −2.5) in period 1, to −2.1 years (−2.4 to −1.8) in 
period 2, to −2.0 years (−2.3 to −1.7) in period 3 
(Ptrend=0.03).
CONCLUSIONS
No evidence of a temporal trend in hazard ratios for 
the association between atrial fibrillation and all 
cause mortality was found. The mean number of life 
years lost to atrial fibrillation at 10 years had improved 
significantly, but a two year gap compared with 
individuals without atrial fibrillation still remained.
Introduction
Atrial fibrillation is the most common sustained 
arrhythmia, with increases in the worldwide incidence 
and prevalence.1-4 The lifetime risk of atrial fibrillation 
is about one in three in men and women aged 55 
and older.5 6 Projections show that the prevalence of 
atrial fibrillation could reach 15.9 million people in 
the United States by 2050 and 17.9 million people in 
Europe by 2060.7 8
Results from the Framingham Heart Study published 
in 1998 showed that newly diagnosed atrial fibrillation 
was associated with an increased risk of death.9 In a 
meta-analysis of 66 cohort studies, atrial fibrillation 
was associated with a 46% relative increase in all 
cause mortality.10 Raised awareness and regular 
publication of updated clinical guidelines have 
facilitated improvements in prognosis after a diagnosis 
of atrial fibrillation. Many studies have shown trends 
for improved short term and long term survival in 
individuals with atrial fibrillation.1 11-13 Previous studies 
did not compare mortality rates between individuals 
with and without atrial fibrillation, however, and data 
on temporal trends for the strength of association 
between atrial fibrillation and death are limited. 
Moreover, previous studies did not account for time 
varying confounding affected by previous exposure.14
Evaluating whether the association between 
atrial fibrillation and death has changed over time is 
essential to understand the success or failure of current 
management of atrial fibrillation. We hypothesized that 
the association between atrial fibrillation and death 
would decline over time. We examined the temporal 
trends in the association between newly diagnosed 
atrial fibrillation and death, measured as a hazard 
ratio and as a difference in restricted mean survival 
times,15 in participants in the Framingham Heart Study 
with nearly 45 years of follow-up.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Newly diagnosed atrial fibrillation is associated with an increased hazard of 
death
Short term and long term survival probabilities in individuals with atrial 
fibrillation have improved over time
WHAT THIS STUDY ADDS
Comparing participants with and without atrial fibrillation in the community 
based Framingham Heart Study, we did not find evidence of temporal trends in 
the relative rate of dying from all causes
The mean number of life years lost to atrial fibrillation at 10 years improved 
significantly over 45 years, but a two year gap compared with individuals without 
atrial fibrillation was still present
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Methods
Data sources
We analyzed data from the Framingham Heart 
Study, a community based cohort study designed to 
investigate risk factors for cardiovascular diseases. 
The original cohort started in 1948 and enrolled 
5209 men and women aged 30-62 from Framingham, 
Massachusetts. Participants underwent standardized 
examinations every other year, including medical 
history, physical examination, laboratory tests, and 
12 lead electrocardiograms. Children of the original 
cohort and their spouses were enrolled in the offspring 
cohort in 1971 (n=5124), and were examined every 
four to eight years.16 Adult children from the offspring 
cohort were enrolled in the third generation cohort in 
2002 (n=4095), and were examined every six to eight 
years.17 The new offspring spouse cohort was started 
in 2003 (n=103), and the Omni 1 (n=506) and Omni 2 
(n=410) cohorts in 1994 and 2003, respectively.
Participants
For practical purposes, we selected three time periods 
based on calendar years and number of participants: 
1972-85, 1986-2000, and 2001-15. In each time 
period, we selected participants who did not have atrial 
fibrillation and were aged 45 or older. We excluded 
participants aged 95 or older or those with prevalent 
atrial fibrillation at the time of entry. We considered 
participants at risk from their age at entry in the 
selected time period until death, age at last follow-up, 
or age at the end of the time period, whichever came 
first. Participants were eligible to re-enter the analyses 
for subsequent time periods, but for different age 
periods, if they were still alive, aged 45-95, and did not 
have atrial fibrillation; in such cases, we updated the 
entry age and the characteristics of each participant at 
the beginning of the next time period (supplementary 
fig S1). We considered each index examination with its 
follow-up period to be a separate person examination.18
We considered participants from examinations 13-
28 (1972-2005) for the original cohort; examinations 
one to nine (1971-2014) for the offspring cohort; 
examinations one to two (2002-14) for the third 
generation cohort; examinations one to two (2003-
11) for the new offspring spouse cohort; examinations 
one to four (1994-2014) for the Omni 1 cohort; and 
examinations one to two (2009-11) for the Omni 2 
cohort (supplementary table S1).
Assessment of newly diagnosed atrial fibrillation
The exposure was newly diagnosed atrial fibrillation 
or atrial flutter as a time varying variable, which was 
assessed until 31 December 2015. Participants were 
classified as having newly diagnosed atrial fibrillation 
if at least two cardiologists from the Framingham 
Heart Study confirmed that atrial fibrillation or atrial 
flutter was found on an electrocardiogram from a 
study examination or from an external clinician, by 
Holter monitoring, or noted on the hospital records. 
Staff from the Framingham Heart Study contacted 
hospital and medical clinics to collect records of 
outpatient appointments and admissions to hospital 
for cardiovascular diseases based on their history of 
health, updated every 24 months. Questions about 
atrial fibrillation (atrial fibrillation and atrial flutter) 
were included in the history of health updates for 
participants outside the clinical visits or admissions to 
hospital.
Outcomes
The primary outcome was all cause mortality. 
Secondary outcomes included cause specific mortality 
categorized as cardiovascular deaths (coronary 
heart disease, cerebrovascular accidents, and other 
cardiovascular causes) and non-cardiovascular deaths 
(cancers, other causes, and unknown causes). A panel 
of three physicians from the Framingham Heart Study 
conducted death reviews based on: hospital admission 
and emergency department records; imaging 
and laboratory reports; physicians’ notes; death 
certificates; autopsy and medical examiners’ reports; 
and a telephone call to family members by a physician 
in the absence of other records.At least two of the three 
members of the review panel were required to agree on 
the cause of death.
Covariates
We considered these clinical characteristics in the 
analyses: current smoking, body mass index, systolic 
and diastolic blood pressure, use of drug treatments 
for hypertension, diabetes mellitus, total cholesterol, 
use of statins, history of heart failure, history of 
myocardial infarction, history of stroke or transient 
ischemic attack, and educational level. Education was 
defined categorically as no high school degree, high 
school degree only, some college but no college degree, 
or a college degree. A panel of three investigators, 
including a neurologist, reviewed all records from 
relevant hospital admissions and clinic reported 
events for a diagnosis of stroke or transient ischemic 
attack. All covariates, except education, were updated 
from the repeated examination cycles.
Statistical analyses
To estimate the association between atrial fibrillation 
and the risk of death, we used Cox proportional hazard 
models. We defined age as the time scale and we 
used the counting process style of input, with at risk 
intervals defined by entry and exit ages. We modeled 
atrial fibrillation as a time varying covariate to account 
for the binary exposure status changing once for some 
participants within a time period from having no atrial 
fibrillation to having atrial fibrillation. By adding 
atrial fibrillation as a time varying covariate to the Cox 
model, the corresponding relative hazard is also time 
varying and no longer a proportional hazards model. 
We estimated hazard ratios with 95% confidence 
intervals. The hazard ratios compared the rate of death 
between individuals with atrial fibrillation and those 
who had not yet developed atrial fibrillation at each 
death time. Model 1 was adjusted for age and sex, 
model 2 was further adjusted for covariates at entry 
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age, and model 3 further accounted for time varying 
covariates. Covariates included current smoking, body 
mass index, systolic and diastolic blood pressure, 
use of drug treatment for hypertension, diabetes 
mellitus, total cholesterol, use of statins, history 
of heart failure, history of myocardial infarction, 
history of stroke or transient ischemic attack, and 
educational level. For model 3, we used marginal 
structural models with inverse probability weighting 
to adjust for time dependent confounding.19 Because 
we examined atrial fibrillation as a time varying 
exposure, a time varying confounder might have 
been present, affected by previous atrial fibrillation 
exposure, that acted as an intermediate in the pathway 
between the atrial fibrillation exposure and the death 
outcome. For example, participants who developed 
atrial fibrillation are at higher risk of developing heart 
failure or myocardial infarction, and heart failure and 
myocardial infarction are associated with an increased 
hazard of death. We analyzed the three time periods 
separately. Trends in hazard ratios across the time 
periods were tested with meta-regression models of log 
hazard ratios against a linear term for time period.
To derive absolute measures of the association 
between atrial fibrillation and death, we also conducted 
a matched cohort analysis (supplementary fig S2). 
Within each time period, we matched each participant 
with atrial fibrillation with up to two referents without 
atrial fibrillation, according to age at diagnosis of 
atrial fibrillation, sex, and the Framingham Heart 
Study cohort. We derived survival curves from age at 
diagnosis of atrial fibrillation for participants and 
referents, adjusted for clinical covariates at age of newly 
diagnosed atrial fibrillation with inverse probability 
weighting.20 We estimated the adjusted difference in 
restricted mean survival times between participants 
with atrial fibrillation and referents at 10 years after a 
diagnosis of atrial fibrillation.21 22 The restricted mean 
survival time quantifies the loss in life expectancy over 
10 years after a diagnosis of atrial fibrillation when 
comparing participants with atrial fibrillation with 
referents. We also tested for temporal trends in the 
differences in restricted mean survival times across the 
time periods by a meta-regression model.
Lastly, we examined cause specific mortality. In each 
time period, we estimated the cumulative incidence of 
cardiovascular deaths and non-cardiovascular deaths 
with the Aalen-Johansen estimator to account for 
competing risks. To assess the association between time 
varying atrial fibrillation and cause specific deaths, we 
used an illness-death model and fitted cause specific 
proportional hazards models with time dependent 
atrial fibrillation (supplementary fig S3). We computed 
hazard ratios with 95% confidence intervals. We used 
the R software 3.6.1 (R Foundation for Statistical 
Computing, Vienna, Austria) with packages survival, 
etm, and ipw, and the akm_rmst function.21
Subgroup and sensitivity analyses
We performed analyses stratified by sex. We also 
performed three sensitivity analyses. First, we 
excluded participants who died within 30 days of 
newly diagnosed atrial fibrillation, to remove the 
effect of comorbidities with a high case fatality 
rate. Second, we categorized newly diagnosed 
participants with atrial fibrillation into those detected 
at a study examination and those diagnosed by 
electrocardiography outside of the Framingham Heart 
Study examinations. We censored participants with 
atrial fibrillation detected at a study examination 
at the time of diagnosis, to account for the fact that 
these participants are more likely to be asymptomatic 
compared with atrial fibrillation detected outside of a 
study examination. Third, we censored participants 
with newly diagnosed atrial fibrillation associated with 
an acute reversible precipitant at the time of diagnosis. 
Secondary precipitants included acute myocardial 
infarction (within 30 days), acute pericardial disease 
surgery (within 30 days), thyrotoxicosis, acute alcohol 
consumption, acute infection, and acute pulmonary 
pathology.23
Missing data
For all analyses, we used multiple imputations to 
account for missing values for body mass index, 
systolic and diastolic blood pressure, smoking 
status, diabetes, drug treatment for hypertension, 
total cholesterol, use of statins, and education. We 
imputed data beginning at examination 11 in the 
original cohort and examination one in the offspring, 
third generation, new offspring spouse, Omni 1, 
and Omni 2 cohorts. We imputed missing covariate 
values at entry examinations and both missing 
covariate values and non-attended examinations 
throughout the follow‐up period. As described 
previously, we used fully conditional specification 
methods to impute values sequentially to account 
for the temporality of covariates across successive 
examination cycles.24 25 Individuals were removed 
from the imputation model at death. We used 
fully conditional specification regression methods 
for continuous variables, and fully conditional 
specification discriminant functions for categorical 
variables. The imputation model included age, 
sex, current smoking, height, weight, systolic 
and diastolic blood pressure, drug treatment for 
hypertension, diabetes mellitus, total cholesterol, 
use of statins, and educational level. We created 
30 imputed datasets and combined estimates with 
Rubin’s rules. We used PROC MI of the SAS software, 
version 9.4 (SAS Institute, Cary, NC) to perform the 
imputation stage.
Patient and public involvement
Funding was not available to train or support patients 
or members of the public to work with us on this study. 
The Framingham Heart Study is ongoing and the 
internal question arose from clinical need; no patients 
were present in this setting. We then appraised these 
secondary data and analyzed them without public or 
patient involvement, as we did not have patients or 
members of the public available to us with the level of 
 on 17 A
ugust 2020 at A
alborg U
niversity Library. P
rotected by copyright.
http://w
w
w
.bm
j.com
/
B
M
J: first published as 10.1136/bm
j.m
2724 on 11 A
ugust 2020. D
ow
nloaded from
 
RESEARCH
4 doi: 10.1136/bmj.m2724 | BMJ 2020;370:m2724 | the bmj
methodological and statistical experience to analyze or 
interpret these results.
Results
Characteristics of participants
We included 10 816 participants without atrial 
fibrillation at entry, of whom 5660 contributed to 
more than one time period (supplementary table S2). 
Supplementary figure S4 shows flow diagrams for the 
selection of participants: 5671 contributed to time period 
1 (1972-85), 6177 to period 2 (1986-2000), and 6174 
to period 3 (2001-15). The proportions of participants 
who were non-smokers, had diabetes, or received drug 
treatment for hypertension increased over time (table 1).
During follow-up, 305 (5.4%) participants developed 
atrial fibrillation in time period 1, 596 (9.6%) in period 
2, and 468 (7.6%) in period 3. For participants with 
atrial fibrillation, mean age at diagnosis, and the 
proportions of participants with diabetes and receiving 
drug treatment for hypertension, increased over time, 
whereas relatively fewer participants had prevalent 
heart failure or myocardial infarction over time (table 
1). In participants with atrial fibrillation, 66 (21.6%) 
were detected during a study examination in time 
period 1, 43 (7.8%) in period 2, and seven (1.5%) in 
period 3 (supplementary table S3). Also, in participants 
with atrial fibrillation, 105 (34.4%) were secondary to 
a precipitant in time period 1, 265 (44.4%) in period 
2, and 201 (42.9%) in period 3 (supplementary table 
S4). The characteristics of participants with atrial 
fibrillation at diagnosis and of their matched referents 
are reported in supplementary table S5.
Temporal trend in the association between newly 
diagnosed atrial fibrillation and all cause mortality
Newly diagnosed atrial fibrillation, compared with 
individuals without atrial fibrillation, was associated 
with an increased hazard of death in all time periods 
and all models (fig 1). In the model adjusted for time 
varying covariates, we found no evidence of a temporal 
trend in hazard ratios (Ptrend=0.70), with a hazard ratio 
of 1.91 (95% confidence interval 1.67 to 2.19) in time 
period 1, 1.42 (1.29 to 1.56) in period 2, and 1.69 (1.47 
to 1.95) in period 3. Results from the matched cohort 
design were also consistent (supplementary table S6).
To assess the loss in lifetime over 10 years after 
a diagnosis of atrial fibrillation, we analyzed 305 
participants with atrial fibrillation and 610 matched 
referents in time period 1, 589 participants and 1170 
referents in period 2, and 453 participants and 892 
referents in period 3. Figure 2 shows the adjusted 
Kaplan-Meier survival curves by time period. The 
adjusted difference in the restricted mean survival time 
at 10 years between participants with atrial fibrillation 
and referents was −2.85 years (95% confidence 
interval −3.21 to −2.50) in time period 1, −2.10 years 
(−2.35 to −1.84) in period 2, and −1.99 years (95% CI 
−2.26 to −1.72) in period 3 (Ptrend=0.03).
Subgroup analysis and sensitivity analyses
In the sex stratified analyses, we found an increased 
hazard of death associated with newly diagnosed 
atrial fibrillation in women and men (table 2). After 
adjusting for time varying covariates, the hazard ratio 
in time period 2 was larger in women than in men 
(1.73 v 1.23, P=0.005) but no evidence of a difference 
between the sexes in time periods 1 and 3 was found 
(P=0.06 and P=0.07, supplementary table S7). We 
found evidence of a decrease in hazard ratios over time 
in women, but not in men. The temporal trends in the 
differences in restricted mean survival times in men 
and women were consistent with the main analysis. 
In men, the difference in restricted mean survival time 
was −2.89 years in time period 1 versus −2.23 years 
Table 1 | Characteristics of participants at entry, and of participants with atrial fibrillation at diagnosis, in each time period
All participants Participants with atrial fibrillation 
Time period 1  
(1972-85; n=5671)
Time period 2  
(1986-2000; n=6177)
Time period 3  
(2001-15; n=6174)
Time period 1  
(1972-85; n=305)
Time period 2 
(1986-2000; n=596)
Time period 3  
(2001-15; n=468)
Age (years) 59.0 (10.5) 59.9 (12.2) 61.0 (12.5) 74.4 (9.5) 76.6 (10.5) 77.8 (10.7)
Sex (% women) 54.6 (n=3094) 56.2 (n=3474) 56.7 (n=3501) 48.2 (n=147) 45.8 (n=273) 45.7 (n=214)
Education (%)
 No high school degree 26.6 (n=1415) 15.3 (n=867) 4.9 (n=278) 42.5 (n=122) 28.6 (n=160) 10.5 (n=47)
 High school degree only 34.1 (n=1810) 31.2 (n=1776) 23.7 (n=1353) 28.9 (n=83) 33.1 (n=185) 32.7 (n=147)
 Some college 21.3 (n=1130) 25.2 (n=1435) 29.6 (n=1685) 16.7 (n=48) 30.6 (n=115) 22.5 (n=101)
 College graduate 18.0 (n=956) 28.3 (n=1610) 41.8 (n=2380) 11.9 (n=34) 17.7 (n=99) 34.3 (n=154)
Systolic blood pressure (mm Hg) 134 (21) 132 (21) 126 (18) 145 (23) 142 (22) 135 (20)
Diastolic blood pressure (mm Hg) 80 (11) 78 (10) 75 (10) 77 (12) 74 (11) 71 (11)
Hypertension treatment (%) 18.9 (n=1070) 26.3 (n=1616) 36.3 (n=2227) 44.4 (n=134) 56.5 (n=331) 65.3 (n=303)
Body mass index 26.4 (4.3) 27.0 (4.9) 28.1 (5.6) 26.3 (4.5) 27.7 (4.9) 28.8 (5.6)
Current smoker (%) 32.1 (n=1789) 20.0 (n=1230) 10.3 (n=635) 20.1 (n=59) 12.5 (n=74) 6.6 (n=31)
Diabetes mellitus (%) 5.7 (n=304) 6.8 (n=402) 10.8 (n=628) 12.3 (n=35) 17.7 (n=83) 22.6 (n=92)
Total cholesterol (mmol/L) 5.8 (1.1) 5.6 (1.1) 4.9 (0.9) 5.7 (1.3) 5.2 (1.1) 4.6 (0.9)
Use of statins (%) 1.8 (n=99) 3.2 (n=198) 28.7 (n=1771) 1.7 (n=5) 8.1 (n=48) 48.5 (n=227)
Previous heart failure (%) 1.1 (n=62) 1.2 (n=75) 1.0 (n=64) 8.5 (n=26) 6.7 (n=40) 4.5 (n=21)
Previous myocardial infarction (%) 4.7 (n=265) 4.7 (n=287) 3.5 (n=213) 15.1 (n=46) 15.1 (n=90) 8.8 (n=41)
Previous stroke or transient 
ischemic attack (%) 2.4 (n=133) 3.1 (n=194) 3.0 (n=184) 12.5 (n=38) 10.6 (n=63) 8.8 (n=41)
Data are mean (standard deviation) or percentage (frequency). Corresponding percentages of missing values for time periods 1, 2, and 3, respectively: body mass index=1.0%, 3.7%, and 6.1%; 
systolic blood pressure=0.1%, 0.1%, and 0.2%; diastolic blood pressure=0.1%, 0.1%, and 0.2%; current smoker=1.7%, 0.2%, and 0.1%; diabetes mellitus=6.1%, 4.5%, and 6.2%; hypertension 
treatment=0.3%, 0.4%, and 0.6%; total cholesterol=3.8%, 5.7%, and 6.1%; use of statins=0.1%, 0.2%, and 0.2%; education=6.3%, 7.9%, and 7.7%.
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in period 3 (Ptrend=0.59); in women, the difference in 
restricted mean survival time was −3.01 years in time 
period 1 versus −1.78 years in period 3 (Ptrend=0.04; 
supplementary fig S5 and fig S6).
In a sensitivity analysis, we removed deaths within 30 
days of a diagnosis of atrial fibrillation and the results 
were consistent (supplementary table S8). Results 
after censoring participants with atrial fibrillation 
detected at a Framingham Heart Study examination 
are reported in supplementary table S9 and figure S7. 
Results after censoring secondary atrial fibrillation 
are reported in supplementary table S10 and figure 
S8. Both sensitivity analyses were consistent with the 
main findings for hazard ratios and for differences in 
restricted mean survival times.
Temporal trend in the association between newly 
diagnosed atrial fibrillation and cause specific 
mortality
We found a decrease in cardiovascular mortality 
over time in all participants, with a lifetime risk of 
cardiovascular death of 35% (95% confidence interval 
32% to 39%) in time period 1 and 16% (13% to 18%) 
in period 3 (supplementary fig S9). In contrast, non-
cardiovascular mortality was similar across the three 
time periods (supplementary fig S10). Across all time 
periods, the association between atrial fibrillation 
and cardiovascular death was larger than for non-
cardiovascular death (table 3). No evidence of change 
over time was found for the association between atrial 
fibrillation and cardiovascular death, whereas the 
strength of association between atrial fibrillation and 
non-cardiovascular death decreased over time (hazard 
ratio 3.2 in time period 1 v 2.0 in time period 3, table 
3). We also used the matched cohort approach to 
estimate the association between atrial fibrillation and 
cause specific mortality (supplementary table S11). 
The results were consistent with the main analyses.
Discussion
Principal findings
Over nearly 45 years of observation in a community 
based cohort, we found that newly diagnosed atrial 
fibrillation was associated with an increased hazard 
of death over three time periods. No evidence of 
a temporal trend in hazard ratios between newly 
diagnosed atrial fibrillation and all cause mortality 
was found. The differences in restricted mean 
survival times 10 years after newly diagnosed atrial 
fibrillation, however, decreased over time, from 2.9 
to 2.0 years of life expectancy after atrial fibrillation, 
between time periods 1 and 3. In the analyses of 
cause specific mortality, we found a decreasing 
trend in the association between atrial fibrillation 
and non-cardiovascular death, but not in relation to 
cardiovascular death.
Possible explanations for our findings
Several reasons could explain a decrease in the 
association between atrial fibrillation and death over 
time. The first clinical guideline recommendations 
for the treatment of atrial fibrillation were published 
in the US in 2001,26 and since then, new evidence 
has regularly been incorporated into updates to 
the guideline. Primary and secondary prevention 
of thromboembolism are important to improve life 
expectancy in individuals with atrial fibrillation.27 28 In 
1954, the US Food and Drug Administration approved 
the use of warfarin, which was the only long term 
anticoagulant drug until the introduction in 2010 of 
non-vitamin K antagonist oral anticoagulants. Vitamin 
K antagonists, such as warfarin, reduced the risk of 
all cause mortality by 26% compared with placebo,29 
whereas non-vitamin K antagonist oral anticoagulants 
reduced all cause mortality by 10% compared with 
warfarin.30 The use of anticoagulation might be 
inadequate as physicians’ adherence to clinical 
Age and sex adjusted model
  1972-85
  1986-2000
  2001-15
Model adjusted for baseline covariates
  1972-85
  1986-2000
  2001-15
Model adjusted for time varying covariates
  1972-85
  1986-2000
  2001-15
3.54 (2.98 to 4.20)
2.31 (2.03 to 2.63)
2.02 (1.73 to 2.37)
3.27 (2.75 to 3.89)
2.25 (1.98 to 2.57)
2.01 (1.71 to 2.36)
1.91 (1.67 to 2.19)
1.42 (1.29 to 1.56)
1.69 (1.47 to 1.95)
1 2 3 4
Time period Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
0.002
0.003
0.7
Ptrend
Fig 1 | Temporal trends for the association between newly diagnosed atrial fibrillation and all cause mortality. Data 
are hazard ratios (95% confidence intervals) for the association between time varying atrial fibrillation and death (in 
participants with v those without atrial fibrillation). Multivariable models were adjusted for the clinical covariates 
listed in table 1. Linear trends across time periods were tested by meta-regression models of log hazard ratios
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recommendations varies, but temporal trends in the 
prescription of anticoagulation suggest improvements 
over time.31 32 Another reason for an expected reduction 
in mortality associated with newly diagnosed atrial 
fibrillation is the potential early identification of 
individuals at low risk because of increased awareness, 
and use of routine electrocardiographs and extended 
electrocardiographic monitoring devices. Individuals 
at low risk might have a more favorable prognosis 
because of starting treatments early for modifiable risk 
factors and prevention of stroke.
As life expectancy of the general population is 
increasing, in part because of reduced mortality rates 
at older ages,33 our findings could indicate a similar 
reduction in mortality rate in individuals with atrial 
fibrillation over time. The reasons for the lack of greater 
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Fig 2 | Adjusted survival curves for participants with atrial fibrillation and matched 
referents. Kaplan-Meier curves since time of diagnosis of atrial fibrillation for 
participants with atrial fibrillation and referents, matched on age at diagnosis of atrial 
fibrillation, sex, and Framingham Heart Study cohort, adjusted for clinical covariates 
at age of diagnosis of atrial fibrillation. The adjusted difference in the restricted mean 
survival time at 10 years between participants with atrial fibrillation and referents is 
the area between the survival curves: −2.85 years (95% confidence interval −3.21 to 
−2.50) in time period 1, −2.10 years (−2.35 to −1.84) in period 2, and −1.99 years (95% 
CI −2.26 to −1.72) in period 3 (Ptrend=0.03)
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improvement in the prognosis in individuals with 
atrial fibrillation are unknown. Individuals with atrial 
fibrillation have a high prevalence of comorbidities and 
the level of multimorbidity reflects the prognosis.34 To 
our knowledge, however, no studies have examined 
the temporal trends in the burden of comorbidities and 
related mortality in participants with atrial fibrillation 
compared with individuals without atrial fibrillation. 
That the burden of comorbidities has grown over time 
because mortality rates in the general population have 
declined is likely,33 and the burden of multimorbidity 
could be related to a prognosis that is difficult to 
improve.
In the analyses of temporal trends, we measured 
the association between atrial fibrillation and death 
with the conventional hazard ratio and the difference 
in restricted mean survival times. Absolute measures 
of association, such as years of life lost, might be 
particularly important in public health decision 
making.35 36 We found that the hazard ratios decreased 
over time when adjusted for age, sex, and baseline 
covariates, but when adjusting for time varying 
confounders, the trend was reduced. Evidence of 
a decreasing trend in the differences in restricted 
mean survival time, however, was found. Interaction 
analysis depends on the analysis scale, and interaction 
on the absolute scale (difference in restricted mean 
survival time) without interaction on the multiplicative 
scale (hazard ratio) is mathematically possible.37 Also, 
detecting interactions with multiplicative models, 
such as the Cox regression model, is uncommon.38 
Results from additive models, however, such as the 
trends seen in years of life lost, might not apply to 
populations other than those with similar risk factor 
distributions as the participants in the Framingham 
Heart Study.38 Another potential explanation for the 
discrepancy is that, in the Cox model, we considered 
participants with no atrial fibrillation; we modeled 
atrial fibrillation as a time varying variable, and we 
adjusted for time varying variables to account for 
differences between participants over the course of 
their trajectories. In contrast, when analyzing restricted 
mean survival times, we considered participants 
with atrial fibrillation and matched referents, and we 
adjusted for fixed covariates at the age of diagnosis of 
atrial fibrillation.
We found evidence of higher all cause mortality 
after a diagnosis of atrial fibrillation in women than in 
men in time period 2 (1986-2000), but no difference 
in hazard ratios between women and men for time 
periods 1 (1972-85) or 3 (2001-15) was found. A 
larger increase in mortality rate after atrial fibrillation 
in women is similar to previous results.9 39 In a recent 
meta-analysis of 30 studies, the ratio of hazard 
ratios for women compared with men was 1.12 (95% 
confidence 1.07 to 1.17).39
Comparison with other studies
Several studies have examined temporal trends in 
survival after newly diagnosed atrial fibrillation.1 11 12 40 
These studies, however, compared participants with 
atrial fibrillation across different years, and most studies 
did not assess the rate of death in participants with 
atrial fibrillation compared with those without atrial 
fibrillation. Hence these temporal trends from previous 
studies do not account for the underlying potential 
improvements in survival of the general population. 
In a study comparing mortality in individuals with 
atrial fibrillation among Medicare beneficiaries, older 
than 65, from 1993 to 2007, with the US general 
population,41 no evidence of improvement in relative 
mortality was found, consistent with the results of our 
study.41
Limitations of the study
Our study had important limitations. We did not have 
enough information on treatments related to atrial 
fibrillation, such as anticoagulation or drug treatments 
for underlying cardiovascular diseases. Previous 
studies showed increased use of anticoagulation 
in patients with atrial fibrillation over time in the 
US.31   42  43 The increasing use of anticoagulation in 
patients with atrial fibrillation partly explains the 
improvement in survival in this group. We combined 
the diagnoses of atrial fibrillation and atrial flutter, 
and included no information on the pattern of atrial 
fibrillation, such as paroxysmal or chronic atrial 
fibrillation, and therefore we could not report on 
temporal trends in specific subtypes. 
The recent establishment of the newest Framingham 
cohorts, including the third generation cohort and the 
Omni 2 cohort, limited the length of follow-up. Also, 
we could not definitively establish a causal relation 
between atrial fibrillation and death, and we cannot 
rule out residual confounding from severity of disease 
or unmeasured factors, such as genetics or variables 
Table 3 | Association between newly diagnosed atrial fibrillation and cause specific mortality
Time period
Hazard ratio (95% CI) for cause specific death between participants with v without atrial fibrillation
Cardiovascular death Non-cardiovascular death
No of 
deaths
Model 1 adjusted 
for age and sex
Model 2 adjusted 
for covariates at 
entry
Model 3 adjusted 
for time varying 
covariates
No of 
deaths
Model 1 adjusted 
for age and sex
Model 2 adjusted 
for covariates at 
entry
Model 3 adjusted 
for time varying 
covariates
1972-85 (n=5671) 425 6.11 (4.76 to 7.85) 5.54 (4.30 to 7.14) 5.00 (3.84 to 6.51) 628 3.16 (2.47 to 4.05) 3.14 (2.45 to 4.03) 3.16 (2.47 to 4.03)
1986-2000 (n=6177) 351 4.18 (3.28 to 5.32) 3.82 (3.00 to 4.87) 2.99 (2.30 to 3.88) 1006 2.65 (2.25 to 3.12) 2.68 (2.28 to 3.16) 2.36 (1.99 to 2.79)
2001-15 (n=6174) 175 6.74 (4.90 to 9.26) 6.63 (4.78 to 9.18) 6.69 (4.80 to 9.31) 747 1.95 (1.61 to 2.38) 2.03 (1.66 to 2.47) 2.04 (1.67 to 2.50)
Ptrend — 0.86 0.76 0.71 — 0.002 0.005 0.008
Data are hazard ratios (95% confidence interval) from an illness death model; cause specific proportional hazards models were fitted with time dependent atrial fibrillation. Models 2 and 3 were 
adjusted for clinical covariates listed in table 1. Linear trends across time periods were tested by meta-regression models of log hazard ratios.
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related to lifestyle. Although the Framingham Heart 
Study included families, we did not account for shared 
environmental factors that could affect the development 
of atrial fibrillation and subsequent hazard of death. 
Previous studies have shown familial aggregation of 
atrial fibrillation.44 In patients with atrial fibrillation, 
however, those with and those without a first degree 
relative affected by atrial fibrillation had a similar risk 
of stroke and coronary events.45
Atrial fibrillation is frequently unrecognized, 
and we acknowledge that temporal trends in earlier 
detection of atrial fibrillation over time might 
be present. The mean age at diagnosis of atrial 
fibrillation has increased over time, however, and 
could be because of improved treatment of cardiac 
risk factors (eg, hypertension, smoking cessation) 
and better management of cardiac conditions (eg, 
heart failure and myocardial infarction), leading 
to a later diagnosis of atrial fibrillation. Moreover, 
participants and referents were matched according to 
age at diagnosis of atrial fibrillation, and our analysis 
compared life expectancy from the same index age 
in each set of participants with atrial fibrillation 
and referents, across all time periods. This finding 
suggests that lead time bias is unlikely to explain our 
findings. 
Also, our multiple imputation analyses assumed 
that covariates were missing at random. We did not 
assess the sensitivity of analyses under the missing-
at-random assumption to the not-missing-at-random 
assumption. Another limitation is that our statistical 
test for temporal trends was based on meta-regression 
across only three time periods and might have limited 
the statistical power, particularly in subgroups of 
men and women. We performed multiple trend tests 
without adjustment for multiplicity and we cannot 
exclude the possibility of spurious findings. Finally, 
our results might not apply to other racial or ethnic 
groups because the Framingham Heart Study has 
mainly European participants.
Conclusions
We found no evidence of a temporal trend in hazard 
ratios between newly diagnosed atrial fibrillation 
and all cause mortality. The hazard ratios for non-
cardiovascular death declined over time but no 
evidence of a temporal trend for cardiovascular death 
was found. Mortality associated with newly diagnosed 
atrial fibrillation remained high compared with 
individuals without atrial fibrillation, despite showing 
some improvements over the past 45 years. More 
than 10 years after a diagnosis of atrial fibrillation, 
individuals with atrial fibrillation lose about two years 
of life compared with matched referents.
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